Tuyển tập báo cáo các nghiên cứu khoa học quốc tế ngành y học dành cho các bạn tham khảo đề tài: The study protocol of the Norwegian randomized controlled trial of electroconvulsive therapy in treatment resistant depression in bipolar disorder | Kessler et al. BMC Psychiatry 2010 10 16 http 1471-244X 10 16 BMC Psychiatry STUDY PROTOCOL Open Access The study protocol of the Norwegian randomized controlled trial of electroconvulsive therapy in treatment resistant depression in bipolar disorder I I Z l zx r r I zx r 1 2A r E s slzxr1 9 I_I zx I I zx c r L zxx rr zx 2 3 If I I I zd zx zx -X -X zzd 1 2 Dzx z D zzx r l x zx I r x23 A A zd zzx -X r r zx zx 5 6 Ute Kessler Arne E vaaler Helle Scnuyen Keill J oedegaard rer Bergsnolm Ole A Andreassen Ulrik F Malt6 7 Gunnar Morken8 9 Abstract Background The treatment of depressive phases of bipolar disorder is challenging. The effects of the commonly used antidepressants in bipolar depression are questionable. Electroconvulsive therapy is generally considered to be the most effective treatment even if there are no randomized controlled trials of electroconvulsive therapy in bipolar depression. The safety of electroconvulsive therapy is well documented but there are some controversies as to the cognitive side effects. The aim of this study is to compare the effects and side effects of electroconvulsive therapy to pharmacological treatment in treatment resistant bipolar depression. Cognitive changes and quality of life during the treatment will be assessed. Methods Design A prospective randomised controlled multi-centre six- week acute treatment trial with seven clinical assessments. Follow up visit at 26 weeks or until remission max 52 weeks . A neuropsychological test battery designed to be sensitive to changes in cognitive function will be used. Setting Nine study centres across Norway all acute psychiatric departments. Sample n 132 patients aged 18 and over who fulfil criteria for treatment resistant depression in bipolar disorder Montgomery Asberg Depression Rating Scale Score of at least 25 at baseline. Intervention Intervention group 3 sessions per week for up to 6 weeks total up to 18 sessions. Control group algorithm-based pharmacological
